The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis

Nils Koch-Henriksen, P S Sorensen, K Bendtzen, Esben Meulengracht Flachs

    25 Citationer (Scopus)

    Abstract

    To establish whether the clinical effect of neutralizing antibodies (NAbs) against interferon-beta (IFN beta) depends on the type of IFNbeta (1a or 1b) used for treatment of patients with relapsing-remitting multiple sclerosis (MS).
    OriginalsprogEngelsk
    TidsskriftMultiple Sclerosis
    Vol/bind15
    Udgave nummer5
    Sider (fra-til)601-5
    Antal sider5
    ISSN1352-4585
    DOI
    StatusUdgivet - 1 maj 2009

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis'. Sammen danner de et unikt fingeraftryk.

    Citationsformater